Presenter warns of unsafe compounded 'copycat' products and urges prescriber training

During the task force session, Dr. Saunders raised safety concerns about compounded and non‑branded products marketed as alternatives to FDA‑approved GLP‑1 and related drugs. She said compounding pharmacies have produced copycat formulations that bypass standard FDA approval and study, and that some of those products are being promoted with predatory marketing to vulnerable patients.

"Compounding does not exist for mass production," she said, adding that shortages provided loopholes that allowed some compounders to create unstudied copycat products. Dr. Saunders described these products as powders sourced largely from overseas and said regulators and enforcement have not fully addressed the practice.

She noted reports of adverse events associated with compounded products and said multiple lawsuits are pending. The presenter and attendees discussed the difference between medically supervised, multidisciplinary programs and commercialized direct‑to‑consumer prescribing platforms; she warned that the latter often lack required labs, monitoring and individualized evaluation.

On gatekeeping, Dr. Saunders said trained clinicians and clinical decision‑support are needed to scale care safely. She compared obesity management’s expected trajectory to prior expansions of primary‑care prescribing for conditions such as hypertension, but said primary care will need more time, training and administrative support — such as help with prior authorizations — to take on broader prescribing responsibilities safely.

The task force heard the safety warnings and a request to consider regulatory and coverage approaches that reduce incentives for unsafe compounded products while expanding access to evidence‑based care.